Opinion
Video
Evolving Goals in Multiple Myeloma Treatment
Experts explore the evolving goals in treating newly diagnosed patients with multiple myeloma, including balancing effective therapies, achieving MRD-negative remission, and managing toxicities.
This is a video synopsis/summary of a Peer Exchange featuring Joshua Richter, MD; Rafat Abonour, MD; Faith Davies, MD; and Amrita Krishnan, MD.
Richter leads a discussion with experts Krishnan and Abonour on evolving goals and approaches in treating newly diagnosed myeloma patients. Krishnan emphasizes the loftier goals of achieving minimal residual disease–negative remission, especially for younger patients, while balancing toxicity for older, frail patients. The conversation delves into treatment strategies for transplant-ineligible patients, exploring clinical trials, such as SWOG S0777 (NCT00644228) and MAIA (NCT02252172). Abonour highlights the importance of tailoring treatment to individual patient characteristics, considering factors such as neuropathy in choosing between regimens. The experts discuss nuances in administering VRd (bortezomib, lenalidomide, dexamethasone) emphasizing the need for personalized approaches to optimize myeloma control and patient outcomes.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
